keyboard_arrow_up

Non Alcoholic Fatty Liver Disease (NAFLD) Research 2016 Covering 13 companies

In-detail Table of Contents of Non-Alcoholic Fatty Liver Disease (NAFLD) Pipeline Market

Companies Involved in Therapeutics Development Arisaph Pharmaceuticals, Inc., AstraZeneca Plc, Betagenon AB, Can-Fite BioPharma Ltd., Conatus Pharmaceuticals Inc., Corcept Therapeutics Incorporated, Daewoong Pharmaceutical Co., Ltd., Dimerix Bioscience Pty Ltd, Dr. Falk Pharma GmbH, DURECT Corporation, Galmed Pharmaceuticals Ltd., Gilead Sciences, Inc., Huons Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Novartis AG, Sancilio & Company, Inc., TaiwanJ Pharmaceuticals Co., Ltd., TCM Biotech International Corp, Tobira Therapeutics, Inc., Verva Pharmaceuticals Limited, Zafgen Inc. and Zydus Cadila Healthcare Limited

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Enquire before buying this research at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=521086 .

Scope for this research:

·         The report provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD)

·         The report reviews pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD) by companies and universities/research institutes based on information derived from company and industry-specific sources

·         The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

·         The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

·         The report reviews key players involved Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics and enlists all their major and minor projects

·         The report assesses Non Alcoholic Fatty Liver Disease (NAFLD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

·         The report summarizes all the dormant and discontinued pipeline projects

·         The report reviews latest news related to pipeline therapeutics for Non Alcoholic Fatty Liver Disease (NAFLD)

The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and features dormant and discontinued projects.

Complete research report at http://www.rnrmarketresearch.com/non-alcoholic-fatty-liver-disease-nafld-pipeline-review-h1-2016-market-report.html .

List of Figures

·         Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2016

·         Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis, H1 2016

·         Number of Products under Development by Companies, H1 2016

·         Comparative Analysis by Clinical Stage Development, H1 2016

·         Comparative Analysis by Early Stage Products, H1 2016

·         Assessment by Monotherapy Products, H1 2016

·         Assessment by Combination Products, H1 2016

·         Number of Products by Top 10 Targets, H1 2016

·         Number of Products by Stage and Top 10 Targets, H1 2016

·         Number of Products by Top 10 Mechanism of Actions, H1 2016

·         Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

·         Number of Products by Routes of Administration, H1 2016

·         Number of Products by Stage and Routes of Administration, H1 2016

·         Number of Products by Stage and Molecule Types, H1 2016